Press & News

The next generation biopharmaceuticals

Press releases

2019-03-28

Interview with Affibody’s CEO (in Swedish)

Older press releases

2019-03-20

Alexion and Affibody Announce Partnership to Co-Develop Anti-FcRn Affibody® Molecule

Solna, Sweden & Boston, USA, March 20, 2019. Affibody AB and Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) today announced a partnership to co-develop ABY-039 for rare Immunoglobulin G (IgG)-mediated autoimmune diseases.[read more]

2019-02-22

Affibody Announces Fully Guaranteed Rights Issue

Solna, Sweden, February 22, 2019. Affibody Medical AB (“Affibody”), a clinical stage biopharmaceutical company developing a pipeline of innovative drug projects, today announced the decision to carry out a capitalization of approximately SEK 150 million through a fully guaranteed...[read more]

2019-02-21

Year End Report 2018

Affibody Medical AB (publ) (“Affibody” or “the Company”), a Swedish biotech company focused on developing next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody® molecules and Albumod™, today issued its Year End Report for 2018.[read more]

Affibodys latest Press releases

2019-06-17

Affibody to Present at Affinity 2019

Solna, Sweden, June 17, 2019. Affibody AB (“Affibody”), a clinical stage biotech company, today announced that Prof. Fredrik Frejd,...[read more]

Affibody in short

Affibody is a Swedish biotech company focused on developing next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody® molecules and Albumod™.

Upcoming reports Financial calendar

Interim Report Q1 (May 17, 2019)

Investor information